PAG
CNCR

Private Advisor Group’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Private Advisor Group’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,355
Closed -$113K – 2285
2023
Q3 		$113K Sell
10,355
-2,600
-20% -$31.7K ﹤0.01% 1954
2023
Q2 		$167K Buy
12,955
+700
+6% +$9.17K ﹤0.01% 1871
2023
Q1 		$147K Sell
12,255
-500
-4% -$6.82K ﹤0.01% 1830
2022
Q4 		$175 Sell
12,755
-2,370
-16% -$34.7K ﹤0.01% 1530
2022
Q3 		$222K Sell
15,125
-9,150
-38% -$148K ﹤0.01% 1627
2022
Q2 		$369K Buy
24,275
+1,850
+8% +$28.4K ﹤0.01% 1546
2022
Q1 		$404K Buy
22,425
+610
+3% +$11.6K ﹤0.01% 1523
2021
Q4 		$519K Buy
21,815
+1,400
+7% +$38.9K ﹤0.01% 1430
2021
Q3 		$620K Hold
20,415
– – ﹤0.01% 1406
2021
Q2 		$651K Buy
20,415
+494
+2% +$14.9K 0.01% 1267
2021
Q1 		$596K Sell
19,921
-744
-4% -$24.2K 0.01% 1220
2020
Q4 		$655K Sell
20,665
-600
-3% -$18K 0.01% 1093
2020
Q3 		$584K Buy
21,265
+230
+1% +$6.15K 0.01% 994
2020
Q2 		$570K Sell
21,035
-3,220
-13% -$79.1K 0.01% 968
2020
Q1 		$474K Buy
24,255
+2,770
+13% +$59.7K 0.01% 914
2019
Q4 		$504K Sell
21,485
-760
-3% -$16.1K 0.01% 1044
2019
Q3 		$417K Buy
22,245
+345
+2% +$7.01K 0.01% 1147
2019
Q2 		$462K Sell
21,900
-2,235
-9% -$46K 0.01% 1084
2019
Q1 		$507K Buy
24,135
+4,950
+26% +$104K 0.01% 963
2018
Q4 		$362K Buy
19,185
+4,050
+27% +$84.4K 0.01% 955
2018
Q3 		$376K Buy
+15,135
New +$372K 0.01% 1116

Other funds holding CNCR

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BBPWM
Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Private Advisor Group's CNCR Position: Q4 2023 in Review

Private Advisor Group sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2023, closing a stake of 10,355 shares — an estimated $113K sold.

Private Advisor Group first reported a position in CNCR in Q3 2018 and held it in 21 quarters. The position peaked at $655K in Q4 2020. 13 funds tracked by Wall St. Rank hold CNCR as of Q4 2023.

  • Private Advisor Group reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2023 after selling out during the quarter.
  • Private Advisor Group sold 10,355 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2023, an estimated $113K.
  • Private Advisor Group first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q3 2018 and held it in 21 quarters.
  • Private Advisor Group's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $655K in Q4 2020.
  • 13 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2023.

Based on Private Advisor Group's 13F filing for Q4 2023, filed 6 Feb 2024.